Share
.webp)
.webp)
.webp)
.webp)
Sandi See Tai
Lexeo Therapeutics, Inc., has announced a series of strategic executive appointments to support the advancement of its pipeline into late-stage clinical development.
“The growing expertise within Lexeo’s leadership has been instrumental in driving some of the most impactful clinical programs, drug approvals, and product launches in rare disease and precision cardiovascular medicine,” said R. Nolan Townsend, Chief Executive Officer of Lexeo Therapeutics. “We are excited to leverage the thought leadership and operational experience of our newly appointed executives as we transition our pipeline towards late-stage clinical studies.”
The new appointment include:
Sandi See Tai, MD has been promoted to Chief Development Officer. Dr. See Tai previously served as Vice President and Development Head for Rare Disease at Pfizer, where she led clinical programs in Rare Cardiovascular, Neurology, Renal, and Pulmonary diseases. During her time at Pfizer, she successfully led the late-stage clinical development of tafamidis for ATTR cardiomyopathy, achieving global regulatory approvals. Dr. See Tai brings nearly 20 years of pharmaceutical industry experience to Lexeo, including roles at Wyeth Pharmaceuticals and academic experience as an Assistant Professor of Pediatrics at Drexel University College of Medicine.
